Announcements
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)
- Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)
- Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
- Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting
- Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers
- Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors
- Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres
- Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)
- Persbericht Biocartis Group NV: Biocartis steunt Borstkankermaand met lancering van een borstkankerportfolio
- Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio
More ▼
Key statistics
On Monday, Biocartis Group NV (8XB:DUS) closed at 0.2585, 1.17% above its 52-week low of 0.2555, set on Sep 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 0.2585 |
Offer | 0.3205 |
Previous close | 0.2585 |
Average volume | -- |
---|---|
Shares outstanding | 93.92m |
Free float | 87.73m |
P/E (TTM) | -- |
Market cap | 27.24m EUR |
EPS (TTM) | -0.9993 EUR |
Data delayed at least 15 minutes, as of Sep 25 2023 07:11 BST.
More ▼